Guardant Health Inc
Suletud
SektorTervishoid
157.41 -0.3
Ülevaade
Aktsiahinna muutus
24h
Min
156.16
Max
158.93
Sissetulek | -8.1M -120M |
|---|---|
Müük | 33M 335M |
Aktsiakasum | -0.89 |
Kasumimarginaal | -35.866 |
Töötajad | 2,490 |
EBITDA | -8.1M -109M |
Järgmine tulemuste avaldamine | 28. okt 2026 |
|---|
Turukapital | 2.4B 22B |
|---|---|
Eelmine avamishind | 157.71 |
Eelmine sulgemishind | 157.41 |
Uudiste sentiment
By Acuity
50%
50%
136 / 339 Pingereas Healthcare
Guardant Health Inc Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Guardant Health Inc Prognoos
Sentiment
By Acuity
136 / 339 Pingereas Tervishoid
Uudiste sentiment
Neutral
Volatiilsus
Alla keskmise
Uudismaht (RCV)
Keskmine
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest Guardant Health Inc
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.